These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 21247791

  • 1. Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.
    Ziebart T, Koch F, Klein MO, Guth J, Adler J, Pabst A, Al-Nawas B, Walter C.
    Oral Oncol; 2011 Mar; 47(3):195-201. PubMed ID: 21247791
    [Abstract] [Full Text] [Related]

  • 2. Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.
    Hagelauer N, Ziebart T, Pabst AM, Walter C.
    Clin Oral Investig; 2015 Jun; 19(5):1079-91. PubMed ID: 25261400
    [Abstract] [Full Text] [Related]

  • 3. The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay.
    Pabst AM, Krüger M, Sagheb K, Ziebart T, Jacobs C, Blatt S, Goetze E, Walter C.
    Clin Oral Investig; 2017 Apr; 21(3):771-778. PubMed ID: 27170294
    [Abstract] [Full Text] [Related]

  • 4. Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.
    Pabst AM, Krüger M, Ziebart T, Jacobs C, Walter C.
    Clin Oral Investig; 2015 Sep; 19(7):1625-33. PubMed ID: 25589370
    [Abstract] [Full Text] [Related]

  • 5. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
    Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B.
    Oral Dis; 2011 Mar; 17(2):194-9. PubMed ID: 20796232
    [Abstract] [Full Text] [Related]

  • 6. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
    Wehrhan F, Hyckel P, Amann K, Ries J, Stockmann P, Schlegel K, Neukam F, Nkenke E.
    Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807
    [Abstract] [Full Text] [Related]

  • 7. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
    Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M.
    J Oral Maxillofac Surg; 2010 Nov; 68(11):2837-45. PubMed ID: 20971371
    [Abstract] [Full Text] [Related]

  • 8. The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: An in vitro study.
    Pabst AM, Krüger M, Ziebart T, Jacobs C, Sagheb K, Walter C.
    J Craniomaxillofac Surg; 2015 Jun; 43(5):688-95. PubMed ID: 25913629
    [Abstract] [Full Text] [Related]

  • 9. Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts.
    Zafar S, Coates DE, Cullinan MP, Drummond BK, Milne T, Seymour GJ.
    Clin Oral Investig; 2016 Nov; 20(8):2023-2035. PubMed ID: 26795621
    [Abstract] [Full Text] [Related]

  • 10. [Bisphosphonates and osteonecrosis of the jaws].
    Urade M.
    Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
    [Abstract] [Full Text] [Related]

  • 11. Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.
    Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T.
    Clin Oral Investig; 2010 Feb; 14(1):35-41. PubMed ID: 19294435
    [Abstract] [Full Text] [Related]

  • 12. Comments on ''Geranylgeraniol--a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw" by Ziebart T et al. (2011).
    Marcuzzi A, Zanin V, Crovella S, Pontillo A.
    Oral Oncol; 2011 May; 47(5):436-7; author reply 438. PubMed ID: 21411362
    [No Abstract] [Full Text] [Related]

  • 13. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 14. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O'Connor TL.
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [Abstract] [Full Text] [Related]

  • 15. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE, Canadian Association of Oral and Maxillofacial Surgeons.
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [Abstract] [Full Text] [Related]

  • 16. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE, Umland EM.
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [Abstract] [Full Text] [Related]

  • 17. Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.
    Cozin M, Pinker BM, Solemani K, Zuniga JM, Dadaian SC, Cremers S, Landesberg R, Raghavan S.
    J Oral Maxillofac Surg; 2011 Oct; 69(10):2564-78. PubMed ID: 21807448
    [Abstract] [Full Text] [Related]

  • 18. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [Abstract] [Full Text] [Related]

  • 19. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA.
    Cancer; 2009 Apr 15; 115(8):1631-7. PubMed ID: 19156913
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws.
    Allegra A, Alonci A, Penna G, Granata A, Nastro Siniscalchi E, Oteri G, Loddo S, Teti D, Cicciù D, De Ponte FS, Musolino C.
    Acta Haematol; 2010 Apr 15; 124(2):79-85. PubMed ID: 20639624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.